TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04569773

Intervention type: BEHAVIORAL
Intervention: Reproductive Concerns Scale
Description: The RCS is a 14-item, 5-point Likert-type self-report measure that assesses concern among cancer survivors whose reproductive ability may have been impaired or lost due to disease and/or treatment. Answers are rated on a 5-point scale (0 to 4), and a single total score is produced by summing responses to all 14 items (range, 0-56 points). A higher score represents more reproductive concerns, and a lower score represents fewer reproductive concerns. In the RCS validation study, internal consistency reliability was 0.91 among long-term female cancer survivors and 0.81 among control women.

Intervention type: BEHAVIORAL
Intervention: Decision Regret Scale
Description: The DRS is a 5-item, 5-point Likert-type self-report measure that assesses distress or remorse after a health-care decision.5 Items are rated on a scale from 1 (strongly agree) to 5 (strongly disagree). Two of the statements (items 2 and 4) are phrased in the negative direction.~A single, total score is produced by first reversing the scores of the 2 negatively phrased items, then taking the mean of the 5 items. This mean is then rescaled to range from 0 to 100 by subtracting 1, then multiplying by 25. A score of 0 indicates no regret, whereas a score of 100 indicates high regret. Internal consistency reliability coefficients for the DRS range from 0.81 to 0.92.
Study: NCT02207647

Intervention type: OTHER
Intervention: no intervention
Study: NCT01767246

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal treatment
Description: Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
Study: NCT03036033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboGlove
Description: All participants are given a Saebo glove to use during their stroke recovery.
Study: NCT02758366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT02702206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
Study: NCT02348788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine + Primaquine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine + Primaquine
Study: NCT00612274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
Study: NCT01785238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal echography
Description: renal echography to analyse the kidney
Study: NCT00643474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Meter
Description: 4-point daily glucose monitoring profile 3 times per week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek Aviva Meter
Description: Frequency and timing of SMBG not specified
Study: NCT04143854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01(Botulinum toxin A)
Description: Intramuscular injection; Dose varies by group
Study: NCT01785238

Intervention type: OTHER
Group type: OTHER
Intervention: renal echography
Description: renal echography to analyse the kidney

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling to analyse different parameters of renal function

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling to analyse different parameters of renal function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: collection of an urine sample
Description: Collection of an urine sample to perform analysis of renal function parameters

Intervention type: OTHER
Group type: OTHER
Intervention: collection of an urine sample
Description: Collection of an urine sample to perform analysis of renal function parameters
Study: NCT02702206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
Study: NCT01768000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Cognitive Adaptation Training
Description: Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
Study: NCT01785238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Blood pressure measurement
Study: NCT02485210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic treatment
Description: It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic treatment
Description: It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
Study: NCT03646253

Intervention type: OTHER
Intervention: Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)
Study: NCT01261533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foldable capsular vitreous body(FCVB)
Description: FCVB with silicone oil inside is tamponaded into the vitreous cavity
Study: NCT04161794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal
Description: 2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
Study: NCT03004690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit A
Description: In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit A
Description: In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit B
Description: Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPE Suit B
Description: Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
Study: NCT00762671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebselen
Description: 150 mg BID for 2 weeks
Study: NCT04143854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01(Botulinum toxin A)
Description: Intramuscular injection; Dose varies by group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection; normal saline
Study: NCT02979262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fathers for Change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Study: NCT02291614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
Study: NCT03244930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor 0.12 mg/kg
Description: Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
Study: NCT01831076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane and tamoxifen
Description: exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
Study: NCT03827993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dedicated sexual health clinic appointment
Description: Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
Study: NCT00845221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 100 mg (Glivec)
Description: 260 mg/m2/day tablets
Study: NCT03882983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antria Cell Preparation Process
Description: Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~* Stromal Vascular Fraction~* Adiployx Biological/Vaccine:
Study: NCT02291614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 211
Description: continuous intravenous infusion (cIV) infusion in cycles from 7 to 28 days
Study: NCT01300546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan/Naproxen Sodium
Description: Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
Study: NCT04278144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDC-1001
Description: Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDC-1001
Description: Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Study: NCT04070573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: High risk pregnant women will be treated with daily aspirin during pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: High risk pregnant women will be treated with daily aspirin during pregnancy.
Study: NCT00762671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 po BID for 2 weeks
Study: NCT04295226

Intervention type: OTHER
Intervention: Structured follow-up after stroke.
Description: Stroke-nurse managed follow-up 3 and 12 months after stroke and multidisciplinary rounds resulting in individual treatment plans for stroke-related health problems.
Study: NCT03146949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sorin Inspire Oxygenator
Description: This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
Study: NCT04628689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block by paraspinous sagittal shift approach
Description: quadratus lumborum block by paraspinous sagittal shift approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadratus lumborum block by paraspinous sagittal shift approach
Description: quadratus lumborum block by paraspinous sagittal shift approach
Study: NCT00734227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency portacaval shunt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emergency TIPS
Study: NCT00670774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: * Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~* Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~* Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~* At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~* In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period
Study: NCT02205944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Handgrip Exercise
Description: Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg \& Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet.
Study: NCT02239783

Intervention type: DEVICE
Intervention: total hip arthroplasty implant
Study: NCT03341910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-03 Lotion, 0.1%
Description: DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazorac Cream, 0.1%
Description: Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DFD-03 Vehicle Lotion 0%
Description: Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tazorac Vehicle Cream 0%
Description: Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
Study: NCT03146949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Affinity Fusion
Description: This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
Study: NCT04168112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza
Description: Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
Study: NCT00409136

Intervention type: BEHAVIORAL
Intervention: Human Alert
Description: An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.

Intervention type: BEHAVIORAL
Intervention: Human Alert
Description: An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
Study: NCT03913585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
Study: NCT02501460

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational handouts
Description: Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational handouts
Description: Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance training
Description: Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation
Description: A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
Study: NCT02474927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)